Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

c-Rel anticorps (pSer503)

c-Rel Reactivité: Humain ELISA, IF Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN7138637
  • Antigène Voir toutes c-Rel Anticorps
    c-Rel (REL proto-oncogene (c-Rel))
    Épitope
    • 18
    • 10
    • 8
    • 7
    • 7
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    pSer503
    Reactivité
    • 85
    • 24
    • 6
    • 5
    • 5
    • 4
    • 4
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    Humain
    Hôte
    • 78
    • 10
    • 1
    Lapin
    Clonalité
    • 71
    • 18
    Polyclonal
    Conjugué
    • 37
    • 9
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp c-Rel est non-conjugé
    Application
    • 61
    • 37
    • 13
    • 13
    • 10
    • 9
    • 4
    • 4
    • 3
    • 3
    • 1
    • 1
    ELISA, Immunofluorescence (IF)
     Réactivité croisée
    Humain
    Purification
    Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
    Immunogène
    Peptide sequence around phosphorylation site of serine 503 (T-S-S(p)-D-S) derived from Human Rel.
    Isotype
    IgG
    Top Product
    Discover our top product c-Rel Anticorps primaire
  • Indications d'application
    IF:1:100-1:200,
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    -20 °C,-80 °C
    Stockage commentaire
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Antigène
    c-Rel (REL proto-oncogene (c-Rel))
    Autre désignation
    REL (c-Rel Produits)
    Synonymes
    anticorps C-Rel, anticorps c-Rel, anticorps NFkB, anticorps c-rel, anticorps zgc:100833, anticorps Xrel2, anticorps Xrel3, anticorps rel, anticorps rel-A, anticorps rel2, anticorps rel3, anticorps v-rel, anticorps xrel, anticorps REL proto-oncogene, NF-kB subunit, anticorps reticuloendotheliosis oncogene, anticorps RELA proto-oncogene, NF-kB subunit, anticorps v-rel avian reticuloendotheliosis viral oncogene homolog, anticorps v-rel avian reticuloendotheliosis viral oncogene homolog L homeolog, anticorps ribonuclease A family member 2 pseudogene, anticorps REL, anticorps Rel, anticorps Rela, anticorps rel, anticorps rel.L, anticorps ECRP
    Sujet

    Background: The REL gene encodes c-Rel, a transcription factor that is a member of the Rel/NFKB family, which also includes RELA (MIM 164014), RELB (604758), NFKB1 (MIM 164011), and NFKB2 (MIM 164012). These proteins are related through a highly conserved N-terminal region termed the 'Rel domain,' which is responsible for DNA binding, dimerization, nuclear localization, and binding to the NFKB inhibitor (MIM 164008) (Belguise and Sonenshein, 2007 (PubMed 18037997)).

    Baeuerle, P.A. and Henkel, T. (1994) Annu Rev Immunol 12, 141-79.
    Baeuerle, P.A. and Baltimore, D. (1996) Cell 87, 13-20.
    Haskill, S. et al. (1991) Cell 65, 1281-9.
    Thompson, J.E. et al. (1995) Cell 80, 573-82.

    Aliases: Avian reticuloendotheliosis antibody, C REL antibody, C Rel protein antibody, c Rel proto oncogene protein antibody, Oncogene REL antibody, Oncogene REL avian reticuloendotheliosis antibody, Proto-oncogene c-Rel antibody, REL antibody, REL_HUMAN antibody, v rel avian reticuloendotheliosis viral oncogene homolog antibody, v rel reticuloendotheliosis viral oncogene homolog antibody, V rel reticuloendotheliosis viral oncogene homolog (avian) antibody

    UniProt
    Q04864
Vous êtes ici: